ABSTRACT Short term variability in FEV1 and responsiveness to inhaled bronchodilator were measured in 150 patients with obstructive ventilatory defects. The range of initial FEV1 was 0 5-4 71 and the natural variability over a 20 minute period when expressed in absolute terms was similar over the entire range, and differed insignificantly from that found in normal subjects. The increase in FEV1 and vital capacity (VC) required to exclude natural variability with 95% confidence in these patients was 160 ml and 330 ml respectively. Natural variability when expressed in percentage terms was negatively correlated with the level of FEV1 recorded. The analysis of changes in FEV1 and VC after administration of bronchodilator used absolute and percentage criteria for response.
Pulmonary function laboratories report the results of bronchodilator tests to clinicians, who then may make decisions about treatment. The criterion used to define a response to bronchodilators therefore requires scrutiny. Any criterion used to define the change in FEV, that is indicative of a response to bronchodilator must take into account the natural short term variability in FEV,; this is true both in routine clinical work and when patients are selected for entry into clinical trials. We have recently reported' that short term variability in FEV1 was constant over a wide range of FEV, in normal subjects and a small group of patients with restrictive ventilatory defects, and therefore suggested that the criterion of response should be an absolute change of 190 ml or more. The possibility remained that patients with severe airflow obstruction might show less natural variability than normal subjects, so that the use of a percentage criterion to define response might be more appropriate in these patients. We group A (n = 72), range of mean FEV, 0 5-1 1 1; group B (n = 51), FEV, 115-2-4 1; group C (n = 27), FEV, 2 45-4-7 1. In addition to the reduced FEV,/VC ratio used as a criterion for entry, all patients were found to have an FEV1I value at least 1 SD lower than the predicted value and most patients in each subgroup had an FEV, more than 2 SD below the mean predicted value.
The differences in FEV, and VC measurements (in millilitres) were expressed both as absolute change (AC) and as percentage change (PC)5: The absolute change in FEV, found after inhalation of bronchodilator ranged from -450 to + 950 ml but the distribution was skewed towards positive differences (figure). Patients were defined as AC responders if they had an increase of 160 FEV, rose (X 2 for trend: p < 0-025); but if the 10% criterion was used the proportion of responders was similar in the three subgroups.
Once the patients had been classified as AC and PC responders, natural variability in FEV, was reexamined to determine whether natural variability before administration of the bronchodilator had been different in the responders and the non-responders. Regardless of which criterion was used to define a response in FEV1, there was no significant difference in AC or PC variability between those who responded and those who did not. In those defined as AC responders the range of response in FEV1 after administration of bronchodilator was 160-500 ml in group A, 160-850 ml in group B, and 160-950 ml in group C; but single patients in groups B and C accounted for the extreme responses (figure). When the Wilcoxon signed rank test 7 was applied to the median increases the response in FEV1 after the bronchodilator was found to be similar in the three groups. In those defined as PC responders the range of response after the bronchodilator was 10-48% in group A, 10-42% in group B, and 10-24% in group C. The percentage response was significantly smaller in group C than in group A.
Discussion
This study of patients referred for bronchodilator tests was carried out prospectively under routine laboratory conditions. The range of natural variability observed is therefore likely to be representative of that encountered in patients with airflow obstruction in normal clinical practice.
We have examined the interaction of natural variability with different selection criteria of the types used in clinical trials based on response to bronchodilators. When absolute change in FEV1 is used to 490 define response, similar numbers of patients are selected at each FEV1 level, with most patients in the lowest FEV1range (group A) failing to show a significant response (table 2) . If the criteria are widened to include absolute change in VC, the number of AC responders increases, with the additional patients coming from the lower FEV1ranges (groups A and B).
Use of a 15% change to define response in FEV1 selects a greater proportion of more severely than of less severely impaired patients. Overall, fewer patients are defined as responders (table 2) . Use of a 10% criterion again selects a greater proportion of more severely impaired patients, but it yields the greatest number of responders overall. It should be noted, however, that many of the increases in FEV1 in those defined as responders by percentage criteria (particularly when 10% is used) fall in the range that is statistically indistinguishable from natural variability. The validity of this type of selection is thereby diminished.
In this study, in contrast to the previous one, no relationship was found between pretest activity and natural variability. The pattern of pretest activity, however, was very different in the two studies, only one patient with airway obstruction having taken moderate exercise before the test. More work is required to resolve this point.
This study does not attempt to examine the clinical importance of the recorded changes in FEV1 and VC. This issue is of particular relevance in two groups of patients. The first group comprises those with an FEV1 of less than I litre who show increases lying within the range of natural variability, which could therefore have occurred by chance. In such patients Tweeddale, Alexander, McHardy any increase may be thought by the clinician to be of some clinical value and the failure to achieve statistical significance tends to be disregarded. The second group comprises patients with a higher FEV1 who achieve changes of statistical significance that may be disregarded because they are not considered to be of clinical importance. If response is to be defined by percentage changes that do not have statistical validity, other evidence must be put forward to justify these assertions. Until this evidence is forthcoming, our study emphasises the need for critical appraisal of whatever criterion is chosen to define response to bronchodilators.
